02-BLOCK WHITENER EL 90

Glavne informacije

  • Zaščiteno ime:
  • 02-BLOCK WHITENER EL 90
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Medicinski pripomoček

Dokumentov

Lokalizacija

  • Na voljo v:
  • 02-BLOCK WHITENER EL 90
    Slovenija
  • Jezik:
  • slovenščina

Drugi podatki

Stanje

  • Source:
  • Ecolab
  • Številka dovoljenja:
  • 913181
  • Zadnja posodobitev:
  • 12-03-2018

Glavnih Značilnosti Zdravila: odmerjanje, interakcije, stranski učinki

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

1 / 13

ODDELEK 1. Identifikacija snovi/zmesi in družbe/podjetja

1.1 Identifikator izdelka

Ime proizvoda

BLOCK WHITENER EL 90

Koda proizvoda

913181-02

Uporaba snovi/zmesi

Čistilo

Vrsta snovi

Zmes

Samo za poklicne uporabnike.

Podatki o redčenju izdelka

Izdelek se prodaja pripravljen za uporabo.

1.2 Pomembne identificirane uporabe snovi ali zmesi in odsvetovane uporabe

Identifikacija uporabe

Čistilo za kuhinje. Ročni postopek

Priporočene omejitve

uporabe

Samo za industrijsko in profesionalno uporabo.

1.3 Podrobnosti o dobavitelju varnostnega lista

Družba

Ecolab d.o.o.

Vajngerlova ulica 4

2000, Maribor Slovenija 02 429 3100 (Delavnik: 8:00 - 16:00)

narocila@ecolab.com

1.4 Telefonska številka za nujne primere

Telefonska številka za nujne

primere

02 429 3100 (Delavnik: 8:00 - 16:00)

Telefonska številka Centra

za zastrupitve

Datum sestavitve/Revizije

29.09.2014

Verzija

ODDELEK 2: Ugotovitev nevarnosti

2.1 Razvrstitev snovi ali zmesi

Razvrstitev (UREDBA (ES) št. 1272/2008)

Jedko za kovine , Kategorija 1

H290

Jedkost za kožo , Kategorija 1.A

H314

Razvrstitev (67/548/EGS, 1999/45/ES)

C; JEDKO

Popolno besedilo stavkov 'R' omenjenih v tem Poglavju, je v Poglavju 16.

Za celotno besedilo H-izjav, omenjeno v tem poglavju, glej 16. poglavje.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

2 / 13

2.2 Elementi etikete

Etiketiranje (UREDBA (ES) št. 1272/2008)

Piktogrami za nevarnost

Opozorilna beseda

Nevarno

Opozorila o nevarnosti

H290

Lahko je jedko za kovine.

H314

Povzroča hude opekline kože in poškodbe oči.

Dopolnilne izjave o

nevarnostih

EUH031

V stiku s kislinami se sprošča strupen plin.

Obvestila o nevarnosti

Preprečevanje:

P280

Nositi zaščitne rokavice/ zaščito za oči/ zaščito

za obraz.

Ukrepanje:

P303 + P361 + P353

PRI STIKU S KOŽO (ali lasmi): takoj

odstraniti/ sleči vsa kontaminirana oblačila.

Izprati kožo z vodo/ prho.

P305 + P351 + P338

PRI STIKU Z OČMI: previdno izpirajte z

vodo nekaj minut. Odstranite kontaktne leče,

če jih imate in če to lahko storite brez težav.

Nadaljujte z izpiranjem.

P310

Takoj pokličite CENTER ZA ZASTRUPITVE ali

zdravnika.

Nevarne komponente, ki morajo biti naštete na nalepki/etiketi:

sodium hydroxide

2.3 Druge nevarnosti

Nobena znana.

ODDELEK 3: Sestava/podatki o sestavinah

3.2 Zmesi

Nevarne sestavine

Kemijsko ime

Št. CAS

ES-št.

Št. REACH

Razvrstitev

(67/548/EGS)

Razvrstitev

(UREDBA (ES) št.

1272/2008)

Koncentracija:

natrijev hipoklorit

7681-52-9

231-668-3

01-2119488154-34

C-N; R31-

R34-R50

Jedkost za kožoKategorija

1.B; H314

Akutna strupenost za vodno

okoljeKategorija 1; H400

>= 2.5 - < 5

Natrijevi/kalcijevi/ma

gnezijevi kloridi

7647-14-5

231-598-3

Xi; R36

Draženje očiKategorija 2;

H319

>= 3 - < 5

Natrijev karbonat

(soda)

497-19-8

207-838-8

01-2119485498-19

Xi; R36

Draženje očiKategorija 2;

H319

>= 1 - < 2.5

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

3 / 13

Milo

822-16-2

212-490-5

Xi; R36

Draženje očiKategorija 2;

H319

>= 1 - < 2.5

a-Olefinsulfonati

36445-71-3

253-040-8

Xn; R22

Xi; R41

N; R51/53

Akutna strupenostKategorija

4; H302

Huda poškodba očiKategorija

1; H318

Kronična strupenost za vodno

okoljeKategorija 2; H411

>= 0.5 - < 1

sodium hydroxide

1310-73-2

215-185-5

01-2119457892-27

C; R35

Jedkost za kožoKategorija

1.A; H314

>= 0.5 - < 1

Popolno besedilo stavkov 'R' omenjenih v tem Poglavju, je v Poglavju 16.

Za celotno besedilo H-izjav, omenjeno v tem poglavju, glej 16. poglavje.

ODDELEK 4: Ukrepi za prvo pomoč

4.1 Opis ukrepov za prvo pomoč

Pri stiku z očmi

Takoj začeti izpirati z obilo vode, tudi pod očesnim vekam,

najmanj 15 minut. Odstranite kontaktne leče, če jih imate in če to

lahko storite brez težav. Nadaljujte z izpiranjem. Takoj pokličite

zdravnika.

Pri stiku s kožo

Takoj umivajte/izpirajte z obilo vode vsaj 15 minut. Po možnosti

uporabljati blago milo. Operite kontaminirana oblačila pred

ponovno uporabo. Pred uporabo temeljito očistiti obutev. Takoj

pokličite zdravnika.

Pri zaužitju

Izprati usta z vodo. NE sprožati bruhanja. Nikoli ne dajajte

nezavestni osebi ničesar peroralno(v usta). Takoj pokličite

zdravnika.

Pri vdihavanju

Potrebna je odstranitev na svež zrak. Simptomatsko zdravljenje.

Če se pojavijo simptomi, poiskati zdravniško pomoč.

4.2 Najpomembnejši simptomi in učinki, akutni in zapozneli

Glej Oddelek 11 za podrobnejše podatke o učinkih na zdravje in simptome.

4.3 Navedba kakršne koli takojšnje medicinske oskrbe in posebnega zdravljenja

Oskrba, obdelava

Simptomatsko zdravljenje.

ODDELEK 5: Protipožarni ukrepi

5.1 Sredstva za gašenje

Ustrezna sredstva za

gašenje:

Uporabljajte gasilne ukrepe, ki so primerni lokalnim okoliščinam in

bližnjemu okolju.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

4 / 13

Neustrezna sredstva za

gašenje

Nobena znana.

5.2 Posebne nevarnosti v zvezi s snovjo ali zmesjo

Specifične nevarnosti med

gašenjem

Izpostavljenje razpadnim proizvodom je lahko nevarno za zdravje.

Nevarni proizvodi izgorevanja

Razkrojni produkti lahko vsebujejo naslednje snovi:

Ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforovi oksidi

5.3 Nasvet za gasilce

Posebne varovalne opreme

za gasilce

: Uporabljajte osebno varovalno opremo.

Dodatne informacije

: Ostanke po požaru in kontaminirano vodo za gašenje požara je

treba varno odstraniti v skladu z lokalnimi uredbami. Pri požaru

in/ali eksploziji ne vdihavajte dima.

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.1 Osebni varnostni ukrepi, zaščitna oprema in postopki v sili

Nasvet za neizučeno osebje

Zagotovite zadostno prezračevanje. Preprečite ljudem dostop do

izpusta/razliva in v protivetrni smeri od izpusta/razliva. Izogibati se

vdihavanju, zaužitju ter stiku s kožo in očmi. Če so delavci

izpostavljeni koncentracijam nad dovoljenimi mejnimi vrednostmi,

morajo uporabljati ustrezno obrazno masko. Zagotovite, da

cišcenje izvaja samo usposobljeno osebje. Informirajte se o

varnostnih ukrepih, naštetih v poglavjih 7 in 8.

Nasvet za reševalce

Če so pri rokovanju z razlitjem zahtevana specialna oblačila,

upoštevati podatke o primernih in neprimernih materialih v

Oddelku 8.

6.2 Okoljevarstveni ukrepi

Okoljevarstveni ukrepi

Preprečiti, da pride v stik z zemljo, površinsko vodo ali podtalnico.

6.3 Metode in materiali za zadrževanje in čiščenje

Metodah za čiščenja

Zaustaviti puščanje, če je varno.Zajezite in zadržite izlitje z

negorljivim absorpcijskim materialom (npr. peskom, zemljo,

diatomejsko zemljo, vermikulitom), in dajte v vsebnik za

odstranjevanje v skladu z lokalnimi/nacionalnimi predpisi (glejte

poglavje 13).Splakniti sledi z vodo.Pri večjih razlitjih zajeziti ali

drugače zadržati razlito snov in s tem zagotoviti, da ne doseže

vodotokov.

6.4 Sklicevanje na druge oddelke

Glej Oddelek 1 za podatke o kontaktu za nujne primere.

Za osebno zaščito glejte poglavje 8.

Glej Oddelek 13 za podatke o dodatni obdelavi odpadkov.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

5 / 13

ODDELEK 7: Ravnanje in skladiščenje

7.1 Varnostni ukrepi za varno ravnanje

Navodilo za varno rokovanje

Ne zaužiti. Preprečiti stik z očmi, kožo ali oblačili. Ne vdihavati

prahu/ dima/ plina/ meglice/ hlapov/ razpršila. Uporabljati samo ob

ustreznem prezračevanju. Po uporabi temeljito umiti roke.

Higienski ukrepi

Ravnajte v skladu z dobro industrijsko higiensko in varnostno

prakso. Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

7.2 Pogoji za varno skladiščenje, vključno z nezdružljivostjo

Zahteve glede skladiščnih

področij in vsebnikov

Ne skladiščite blizu kislin. Hraniti zunaj dosega otrok. Hraniti v

tesno zaprti posodi. Hraniti v posodah z ustreznimi nalepkami.

Temperatura pri skladiščenju

5 °C do 40 °C

7.3 Posebne končne uporabe

Posebni način(-i) uporabe

Čistilo za kuhinje. Ročni postopek

ODDELEK 8: Nadzor izpostavljenosti/osebna zaščita

8.1 Parametri nadzora

Mejne vrednosti za poklicno izpostavljenost

Št. CAS

Komponente

Tip vrednosti

(Oblika

izpostavljanja)

Parametri nadzora

Sprememba

Osnova

1310-73-2

sodium

hydroxide

MV (Inhalabilna

frakcija)

2 mg/m3

2011-06-01

SI OEL

8.2 Nadzor izpostavljenosti

Ustrezni inženirski mehanizmi

Tehnični ukrepi

Učinkovit izpušni prezračevalni sistem. Ohranjati vrednosti

koncentracij v zraku znotraj standardov za poklicno

izpostavljenost.

Individualni zaščitni ukrepi

Higienski ukrepi

Ravnajte v skladu z dobro industrijsko higiensko in varnostno

prakso. Odstranite in operite kontaminirana oblačila pred ponovno

uporabo. Po uporabi temeljito umiti obraz, roke in izpostavljeno

kožo. V primeru nevarnosti, kjer bi lahko prišlo do stika ali

brizganja, zagotoviti ustrezne prostore in pripomočke za hitro

polivanje ali izpiranje oči in telesa.

Zaščito za oči / obraz (EN

Varovalna očala

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

6 / 13

166)

Obrazni ščitnik

Zaščita rok (EN 374)

Nosite naslednjo osebno zaščitno opremo:

Nitrilni kavčuk

butilni kavčuk

Neprepustne rokavice

Če se pojavijo kakršni koli znaki razkroja rokavic ali prodora

kemikalij skozi rokavice, je treba le-te odstraniti in jih zamenjati z

novimi.

Zaščita kože in telesa (EN

14605)

Osebna zaščitna oprema, vsebujoč: prilegajoče se zaščitne

rokavice, zaščitna očala in zaščitno obleko

Zaščita dihal (EN 143,

14387)

Ni potrebna, če se koncentracija nevarnih snovi v zraku ohrani

pod mejnimi vrednostmi, navedenimi v podatkih o mejnih

vrednostih izpostavitve. Uporabiti certificirano dihalno napravo,

skladno z zahtevami Direktiv 89/656/EGS in 89/686/EGS ali

enakovredno, kadar se tveganju za dihala ni mogoče izogniti s

tehničnimi varovalnimi sredstvi in ukrepi, metodami ali postopki

organizacije dela.

Nadzor izpostavljenosti okolja

Splošna navodila

: Upoštevati dolocilo o ograjevanju okoli posod za shranjevanje.

ODDELEK 9: Fizikalne in kemijske lastnosti

9.1 Podatki o osnovnih fizikalnih in kemijskih lastnostih

Videz

: gel

Barva

: opačna, zelena

Vonj

: Klor

12.4, 100 %

Plamenišče

Se ne upošteva., Ne pospešuje gorenja.

Mejne vrednosti vonja

Ni razpoložljivih podatkov

Tališče/ledišče

Ni razpoložljivih podatkov

Začetno vrelišče in območje

vrelišča

> 100 °C

Hitrost izparevanja

Ni razpoložljivih podatkov

Vnetljivost (trdno, plinasto)

Ni razpoložljivih podatkov

Zgornja eksplozivna meja

Ni razpoložljivih podatkov

Spodnja eksplozivna meja

Ni razpoložljivih podatkov

Parni tlak

Ni razpoložljivih podatkov

Relativna gostota par/hlapov

Ni razpoložljivih podatkov

Relativna gostota

0.98 - 1.04

Topnost v vodi

topnost v maščobah

Topnost v drugih topilih

Ni razpoložljivih podatkov

Porazdelitveni koeficient: n-

oktanol/voda

Ni razpoložljivih podatkov

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

7 / 13

Temperatura samovžiga

Ni razpoložljivih podatkov

Toplotni razpad/razgradnja

Ni razpoložljivih podatkov

Viskoznost, kinematična

Ni razpoložljivih podatkov

Eksplozivne lastnosti

Ni razpoložljivih podatkov

Oksidativne lastnosti

9.2 Drugi podatki

Ni razpoložljivih podatkov

ODDELEK 10: Obstojnost in reaktivnost

10.1 Reaktivnost

Nevarne reakcije pri normalni uporabi niso znane.

10.2 Kemijska stabilnost

Stabilno pri normalnih pogojih.

10.3 Možnost poteka nevarnih reakcij

Nevarne reakcije pri normalni uporabi niso znane.

10.4 Pogoji, ki se jim je treba izogniti

Nobena znana.

10.5 Nezdružljivi materiali

Kisline

Kovine

10.6 Nevarni produkti razgradnje

Razkrojni produkti lahko vsebujejo naslednje snovi:

Ogljikova oksida

Dušikovi oksidi (NOx)

Žveplovi oksidi

Fosforovi oksidi

ODDELEK 11: Toksikološki podatki

11.1 Podatki o toksikoloških učinkih

Podatki o možnih načinih

izpostavljenosti

Vdihavanje, Stik z očmi, Stik s kožo

Strupenost

Akutna oralna toksičnost

: Za ta proizvod ni na voljo podatkov.

Akutna toksičnost pri

vdihavanju

: Za ta proizvod ni na voljo podatkov.

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

8 / 13

Akutno dermalno strupenost

: Za ta proizvod ni na voljo podatkov.

Jedkost za kožo/draženje

kože

: Za ta proizvod ni na voljo podatkov.

Resne okvare oči/draženje

: Za ta proizvod ni na voljo podatkov.

Preobčutljivost pri vdihavanju

in preobčutljivost kože

: Za ta proizvod ni na voljo podatkov.

Rakotvornost

: Za ta proizvod ni na voljo podatkov.

Učinki na razplojevanje

: Za ta proizvod ni na voljo podatkov.

Mutagenost za zarodne

celice

: Za ta proizvod ni na voljo podatkov.

Teratogenost

: Za ta proizvod ni na voljo podatkov.

STOT - enkratna

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

STOT - ponavljajoča se

izpostavljenost

: Za ta proizvod ni na voljo podatkov.

Toksičnost pri vdihavanju

: Za ta proizvod ni na voljo podatkov.

Komponente

Akutna oralna toksičnost

: natrijev hipoklorit

LD50 Podgana: 5,230 mg/kg

Natrijevi/kalcijevi/magnezijevi kloridi

LD50 Podgana: 3,000 mg/kg

Natrijev karbonat (soda)

LD50 Podgana: 2,800 mg/kg

Milo

LD50 Podgana: > 5,000 mg/kg

a-Olefinsulfonati

LD50 Podgana: > 1,500 mg/kg

Komponente

Akutna toksičnost pri

vdihavanju

: natrijev hipoklorit

1 h LC50 Podgana: > 10,500 mg/l

Komponente

Akutno dermalno strupenost

: natrijev hipoklorit

LD50 Kunec: > 10,000 mg/kg

Natrijevi/kalcijevi/magnezijevi kloridi

LD50 Kunec: > 10,000 mg/kg

Milo

LD50 Kunec: > 3,000 mg/kg

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

9 / 13

Možni učinki na zdravje

Oči

Povzroča hude poškodbe oči.

Koža

Povzroča težke opekline kože.

Zaužitje

Povzroča opekline prebavnega trakta.

Vdihavanje

Lahko povzroči draženje nosu, grla in pljuč.

Kronična izpostavljenost

Pri normalni rabi ni znano ali pričakovano, da bi škodovalo

zdravju.

Izkušnje z izpostavljenostjo človeka

Stik z očmi

Rdečina, Bolečina, Razjede

Stik s kožo

Rdečina, Bolečina, Razjede

Zaužitje

Razjede, Želodčna bolečina

Vdihavanje

Razdraženost dihal, Kašelj

ODDELEK 12: Ekološki podatki

12.1 Ekotoksičnost

Učinki na okolje

Ta proizvod nima znanih strupenih učinkov na okolje.

Proizvod

Strupenost za ribe

: Ni razpoložljivih podatkov

Strupenost za vodno bolho in

druge vodne vretenčarje.

: Ni razpoložljivih podatkov

Strupenost za alge

: Ni razpoložljivih podatkov

Komponente

Strupenost za ribe

: Natrijevi/kalcijevi/magnezijevi kloridi

96 h LC50 Ribe : 5,840 mg/l

Milo

96 h LC50 Ribe : 7.44 mg/l

a-Olefinsulfonati

96 h LC50 Ribe : 3 mg/l

Komponente

Strupenost za vodno bolho in

druge vodne vretenčarje.

: Natrijev karbonat (soda)

48 h EC50 Daphnia (Vodna bolha): 200 mg/l

sodium hydroxide

48 h EC50: 40 mg/l

12.2 Obstojnost in razgradljivost

Ni razpoložljivih podatkov

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

10 / 13

12.3 Zmožnost kopičenja v organizmih

Ni razpoložljivih podatkov

12.4 Mobilnost v tleh

Ni razpoložljivih podatkov

12.5 Rezultati ocene PBT in vPvB

Proizvod

Ocena

Snov/mešanica ne vsebuje komponent, ki so obstojne,

bioakumulacijske in strupene (PBT) ali izredno obstojne in zelo

bioakumulacijske (vPvB) v koncentracijah 0,1% ali več.

12.6 Drugi škodljivi učinki

Ni razpoložljivih podatkov

ODDELEK 13: Odstranjevanje

Odložiti v skladu z evropskimi direktivami o odpadkih in nevarnih odpadkih.Odpadkom naj bi kode

pripisal uporabnik, prednostno po posvetu z organi, ki so pristojni za odstranjevanje odpadkov.

13.1 Metode ravnanja z odpadki

Proizvod

: Kjer je mogoče, ima recikliranje prednost pred odlaganjem ali

sežiganjem. Če recikliranje ni izvedljivo, odstranite v skladu z

lokalnimi uredbami. Odpad odlagajte v odobrenih objektih za

odlaganje odpada.

Kontaminirana

embalaža/pakiranje

: Odstranite kot nerabljen proizvod. Prazne posode je treba

dostaviti pooblaščeni osebi za ravnanje z odpadki na recikliranje

ali odlaganje. Prazni vsebniki niso za ponovno uporabo.

Evropski katalog odpadkov

: 200115* - alkalije

ODDELEK 14: Podatki o prevozu

Špediter/pošiljatelj/dobavitelj je odgovoren zagotoviti, da so embalaža, oznake in nalepke za

označevanje nevarnosti skladni z izbranim načinom prevoza.

Transport po kopnem (ADR/ADN/RID)

14.1 Številka ZN

1824

14.2 Pravilno odpremno ime

RAZTOPINA NATRIJEVEGA HIDROKSIDA

14.3 Razredi nevarnosti

prevoza

14.4 Skupina embalaže

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

Nobenega

Zračni transport (IATA)

14.1 Številka ZN

1824

14.2 Pravilno odpremno ime

Sodium hydroxide solution

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

11 / 13

14.3 Razredi nevarnosti

prevoza

14.4 Skupina embalaže

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

Nobenega

Pomorski transport

(IMDG/IMO)

14.1 Številka ZN

1824

14.2 Pravilno odpremno ime

SODIUM HYDROXIDE SOLUTION

14.3 Razredi nevarnosti

prevoza

14.4 Skupina embalaže

14.5 Nevarnosti za okolje

14.6 Posebni previdnostni

ukrepi za uporabnika

Nobenega

14.7 Prevoz v razsutem

stanju v skladu s Prilogo II k

MARPOL 73/78 in Kodeksom

IBC

Se ne upošteva.

ODDELEK 15: Zakonsko predpisani podatki

15.1 Predpisi/zakonodaja o zdravju, varnosti in okolju, specifični za snov ali zmes

Nacionalni predpis

Upoštevajte direktivo 94/33/ES za varnost in zdravje pri delu mladoletnih oseb.

Razred skladiščenja

Drugi predpisi

Zakon o kemikalijah

Pravilnik o tehničnih in organizacijskih ukrepih za skladiščenje

nevarnih kemikalij

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti kemičnim snovem pri delu

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti rakotvornim ali mutagenim snovem

Pravilnik o osebni varovalni opremi, ki jo delavci uporabljajo pri

delu

Pravilnik o varovanju zdravja pri delu otrok, mladostnikov in

mladih oseb

Pravilnik o varovanju zdravja pri delu nosečih delavk, delavk, ki so

pred kratkim rodile ter doječih

Zakon o varstvu okolja

Uredba o odpadkih

Uredba o ravnanju z embalažo in odpadno embalažo

Zakon o prevozu nevarnega blaga

15.2 Ocena kemijske varnosti

Izdelek vsebuje snovi, za katere se še vedno zahtevajo ocene kemijske varnosti.

ODDELEK 16: Drugi podatki

Celotno besedilo R-stavkov

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

12 / 13

Zdravju škodljivo pri zaužitju.

V stiku s kislinami se sprošča strupen plin.

Povzroča opekline.

Povzroča hude opekline.

Draži oči.

Nevarnost hudih poškodb oči.

Zelo strupeno za vodne organizme.

R51/53

Strupeno za vodne organizme, lahko povzroči dolgotrajne škodljive

učinke na vodno okolje.

Celotno besedilo H-stavkov

H302

Zdravju škodljivo pri zaužitju.

H314

Povzroča hude opekline kože in poškodbe oči.

H318

Povzroča hude poškodbe oči.

H319

Povzroča hudo draženje oči.

H400

Zelo strupeno za vodne organizme.

H411

Strupeno za vodne organizme, z dolgotrajnimi učinki.

Celotno besedilo drugih okrajšav

Pripravil

Regulatory Affairs

Števila navedena v varnostnem listu so podana v obliki: 1,000, 000=1 milijon in 1,000=1 tisoč. 0.1

= 1 deseti in 0.001 = 1 tisoči.

SPREMEMBE PODATKOV: Pomembne spremembe podatkov o predpisih in zdravju pri tej

popravljeni izdaji so nakazane s crto ob levem robu varnostnega lista.

Informacija v tem Varnostnem podatkovnem listu je pravilna po našem najboljšem znanju,

informacijah in prepričanju na dan njegove objave. Informacija je zasnovana samo kot napotilo za

varno rokovanje, uporabo, obdelavo/predelavo, shranjevanje/skladiščenje, transport,

odstranjevanje in izpust in ne sme biti interpretirana kot specifikacija jamstev in kakovosti.

Informacija se nanaša samo na označeni specifični material in morda ne bo veljavna za tak

material, če bo uporabljen v kombinaciji s kakšnim drugim materialom ali postopkom, razen če to

ni posebej navedeno v tekstu.

PRILOGA: SCENARIJI IZPOSTAVLJENOSTI

Snovi po DPD+:

:

Naslednje snovi so glavne sestavine, ki prispevajo k scenariju izpostavljenosti za zmesi, skladno z

metodologijo DPD+:

Pot

Snov

Št. CAS

Št. EINECS

Zaužitje

sodium hydroxide

1310-73-2

215-185-5

Vdihavanje

sodium hydroxide

1310-73-2

215-185-5

Kožno

sodium hydroxide

1310-73-2

215-185-5

Oči

sodium hydroxide

1310-73-2

215-185-5

vodno okolje

natrijev hipoklorit

a-Olefinsulfonati

7681-52-9

36445-71-3

231-668-3

253-040-8

VARNOSTNI LIST

v skladu z Uredbo (ES) št. 1907/2006

BLOCK WHITENER EL 90

913181-02

13 / 13

Fizikalne lastnosti snovi po DPD+:

Snov

Parni tlak

Topnost v vodi

Pow

Molska masa

sodium hydroxide

55 hPa

100 g/ml

40 g/mol

natrijev hipoklorit

25 hPa

1,000 g/l

Za preračun, ali so vaši nadaljnji pogoji obratovanja in ukrepi za obvladovanje tveganja varni,

prosimo, izračunajte faktor tveganja na spodaj navedeni spletni strani:

www.ecetoc.org/tra

Kratek naslov scenarija

izpostavljenosti

Čistilo za kuhinje. Ročni postopek

Deskriptorji uporabe

Glavne skupine uporabnikov

Poklicne uporabe: javna uporaba (uprava, izobraževanje,

razvedrilo, storitve, obrt)

Sektorji končne uporabe

SU22: Poklicne uporabe: javna uporaba (uprava, izobraževanje,

razvedrilo, storitve, obrt)

Skupine postopkov

PROC10: Nanašanje z valjčkom ali čopičem

PROC8a: Prenos snovi ali pripravka (polnjenje/ praznjenje) iz/ v

posode/ velike vsebnike na nenamenskih napravah

Kategorije izdelka

PC35: Izdelki za pranje in čiščenje (vključno z izdelki na osnovi

topil)

Kategorije sproščanja v

okolje

ERC8a: Močno razpršena notranja uporaba procesnih

pripomočkov v odprtih sistemih

11-12-2018

FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications

FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications

FDA update on the ongoing investigation into angiotensin II receptor blocker impurities, recalls and current findings.

FDA - U.S. Food and Drug Administration

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

17-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Published on: Fri, 16 Nov 2018 The food enzyme is an endo‐1,4‐β‐xylanase (EC 3.2.1.8) produced with a genetically modified strain of Aspergillus oryzae by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This xylanase is intended to be used in baking and cereal‐based processes. Based on the proposed maximum use levels, dietary exposure to the food enzyme–total organic solids (TOS) was e...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐α‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐SO by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme–total organi...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

7-11-2018

Enforcement Report for the Week of November 07, 2018

Enforcement Report for the Week of November 07, 2018

Recently Updated Records for the Week of November 07, 2018 Last Modified Date: Friday, November 02, 2018

FDA - U.S. Food and Drug Administration

6-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for kresoxim‐methyl

Evaluation of confirmatory data following the Article 12 MRL review for kresoxim‐methyl

Published on: Fri, 02 Nov 2018 00:00:00 +0100 The applicant BASF SE submitted a request to the competent national authority in Belgium to evaluate the confirmatory data that were identified for kresoxim‐methyl in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the confirmatory data requirement, a new study on the storage stability of kresoxim‐methyl residues in animal matrices was submitted. The data gap was considered ...

Europe - EFSA - European Food Safety Authority Publications

6-11-2018

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Published on: Fri, 02 Nov 2018 00:00:00 +0100 In accordance with Article 6 of Regulation (EC) No 396/2005, the Australian Government Department of Agriculture and Water Resources submitted two requests to the competent national authority in Denmark to set import tolerances for the active substance haloxyfop‐P in linseed and rapeseed. The data submitted in support of the request were found to be sufficient to derive maximum residue level (MRL) proposals for linseed and rapeseed. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucan 1,4‐α‐glucosidase (EC 3.2.1.3) is produced with the genetically modified Aspergillus niger strain NZYM‐BW by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucan 1,4‐α‐glucosidase food enzyme is intended to be used in distilled alcohol production and starch processing for the production of glucose syrups. Residu...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

29-10-2018

BFB Be Fast Block Capsules

BFB Be Fast Block Capsules

BFB Be Fast Block Capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to consider in this revision 2 of Flavouring Group Evaluation 201, the additional data on genotoxicity submitted by the Industry on two substances, 2‐methylpent‐2‐enal [FL‐no: 05.090] and 2 methylcrotonaldehyde [FL‐no: 05.095], from subgroup 1.1.2 of FGE.19. In FGE.201Rev1, the Panel concluded that further data were required in order to clarify the genotoxic poten...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Minister za zdravje na 90. obletnici ZD Celje

Minister za zdravje na 90. obletnici ZD Celje

Minister za zdravje Samo Fakin se je danes udeležil 90. obletnice Zdravstvenega doma Celje. Na...

Ministrstvo za zdravje

27-9-2018

Enforcement Report for the Week of November 02, 2016

Enforcement Report for the Week of November 02, 2016

Recently Updated Records for the Week of November 02, 2016 Last Modified Date: Thursday, September 27, 2018

FDA - U.S. Food and Drug Administration

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

30-8-2018

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Cyprus and EFSA – Final report

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Cyprus and EFSA – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 Cyprus alongside with another 4 countries has participated successfully in the Grant Agreement GP/EFSA/DATA/2016/01‐GA 02, entitled: “Strategic Partnership with Cyprus on Data Quality”. The project was co‐financed by EFSA, aiming to help both EFSA and data providers from Member States to possess data of high quality in a quantitatively manageable way. The main objective of the grant agreement was the establishment of the data governance, coordination and imp...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

EU/3/15/1567 (TMC Pharma (EU) Limited)

EU/3/15/1567 (TMC Pharma (EU) Limited)

EU/3/15/1567 (Active substance: Recombinant human interleukin-3 truncated diphtheria toxin fusion protein) - Transfer of orphan designation - Commission Decision (2018)7816 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/064/15/T/02

Europe -DG Health and Food Safety

15-11-2018

alitretinoin

alitretinoin

alitretinoin (Active substance: alitretinoin) - Centralised - Art 28 - (PSUR - Commission Decision (2018)7675 of Thu, 15 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/90/201801

Europe -DG Health and Food Safety

13-11-2018

EU/3/17/1863 (Celgene Europe B.V.)

EU/3/17/1863 (Celgene Europe B.V.)

EU/3/17/1863 (Active substance: Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains) - Transfer of orphan designation - Commission Decision (2018)7574 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/270/16/02

Europe -DG Health and Food Safety

22-10-2018

EU/3/01/075 (Eisai GmbH)

EU/3/01/075 (Eisai GmbH)

EU/3/01/075 (Active substance: Denileukin diftitox) - Transfer of orphan designation - Commission Decision (2018)6991 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/038/01/T/02

Europe -DG Health and Food Safety

22-10-2018

EU/3/05/264 (Roche Registration GmbH)

EU/3/05/264 (Roche Registration GmbH)

EU/3/05/264 (Active substance: Cholest-4-en-3-one, oxime) - Transfer of orphan designation - Commission Decision (2018)6995 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/OD/081/04/T/02

Europe -DG Health and Food Safety

22-10-2018

EU/3/15/1495 (Ultragenyx Netherlands B.V.)

EU/3/15/1495 (Ultragenyx Netherlands B.V.)

EU/3/15/1495 (Active substance: Triheptanoin) - Transfer of orphan designation - Commission Decision (2018)6992 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/007/15/T/02

Europe -DG Health and Food Safety

2-10-2018

Zavesca (Janssen-Cilag International NV)

Zavesca (Janssen-Cilag International NV)

Zavesca (Active substance: Miglustat) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5472 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000435/T/0063

Europe -DG Health and Food Safety

2-10-2018

Dynastat (Pfizer Europe MA EEIG)

Dynastat (Pfizer Europe MA EEIG)

Dynastat (Active substance: Parecoxib ) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6471 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000381/T/0073

Europe -DG Health and Food Safety

2-10-2018

Retacrit (Pfizer Europe MA EEIG)

Retacrit (Pfizer Europe MA EEIG)

Retacrit (Active substance: epoetin zeta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6481 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/872/T/86

Europe -DG Health and Food Safety

2-10-2018

HALAVEN (Eisai GmbH)

HALAVEN (Eisai GmbH)

HALAVEN (Active substance: eribulin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6457 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2084/T/46

Europe -DG Health and Food Safety

2-10-2018

Lamivudine Teva Pharma B.V. (Teva B.V.)

Lamivudine Teva Pharma B.V. (Teva B.V.)

Lamivudine Teva Pharma B.V. (Active substance: Lamivudine) - Centralised - Yearly update - Commission Decision (2018)6476 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Imraldi (Samsung Bioepis UK Limited)

Imraldi (Samsung Bioepis UK Limited)

Imraldi (Active substance: adalimumab) - Centralised - 2-Monthly update - Commission Decision (2018)6458 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4279/IB/14

Europe -DG Health and Food Safety

2-10-2018

Intuniv (Shire Pharmaceuticals Ireland Limited)

Intuniv (Shire Pharmaceuticals Ireland Limited)

Intuniv (Active substance: guanfacine) - Centralised - Yearly update - Commission Decision (2018)6473 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Nexium Control (Pfizer Healthcare Ireland)

Nexium Control (Pfizer Healthcare Ireland)

Nexium Control (Active substance: esomeprazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6474 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/002618/T/0023

Europe -DG Health and Food Safety

2-10-2018

Ritemvia (Celltrion Healthcare Hungary Kft.)

Ritemvia (Celltrion Healthcare Hungary Kft.)

Ritemvia (Active substance: rituximab) - Centralised - Yearly update - Commission Decision (2018)6480 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Uptravi (Janssen-Cilag International NV)

Uptravi (Janssen-Cilag International NV)

Uptravi (Active substance: selexipag) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6470 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3774/T/19

Europe -DG Health and Food Safety

2-10-2018

Zoledronic acid Actavis (Actavis Group PTC ehf.)

Zoledronic acid Actavis (Actavis Group PTC ehf.)

Zoledronic acid Actavis (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)6488 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Metalyse (Boehringer Ingelheim International GmbH)

Metalyse (Boehringer Ingelheim International GmbH)

Metalyse (Active substance: tenecteplase) - Centralised - Yearly update - Commission Decision (2018)6489 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

NexoBrid (MediWound Germany GmbH)

NexoBrid (MediWound Germany GmbH)

NexoBrid (Active substance: Concentrate of proteolytic enzymes enriched in bromelain) - PSUSA - Modification - Commission Decision (2018)6460 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10028/201712

Europe -DG Health and Food Safety

2-10-2018

EU/3/14/1242 (Neurolixis SAS)

EU/3/14/1242 (Neurolixis SAS)

EU/3/14/1242 (Active substance: 3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone) - Transfer of orphan designation - Commission Decision (2018)6436 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/163/13/T/01

Europe -DG Health and Food Safety

2-10-2018

Trizivir (ViiV Healthcare BV)

Trizivir (ViiV Healthcare BV)

Trizivir (Active substance: abacavir, lamivudine, zidovudine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6483 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/338/T/108

Europe -DG Health and Food Safety

2-10-2018

EU/3/16/1786 (Voisin Consulting S.A.R.L.)

EU/3/16/1786 (Voisin Consulting S.A.R.L.)

EU/3/16/1786 (Active substance: Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein) - Transfer of orphan designation - Commission Decision (2018)6427 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/183/16/T/02

Europe -DG Health and Food Safety

2-10-2018

Telzir (ViiV Healthcare BV)

Telzir (ViiV Healthcare BV)

Telzir (Active substance: Fosamprenavir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6468 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/534/T/93

Europe -DG Health and Food Safety

2-10-2018

Pemetrexed Pfizer (Pfizer Europe MA EEIG)

Pemetrexed Pfizer (Pfizer Europe MA EEIG)

Pemetrexed Pfizer (Active substance: pemetrexed) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6464 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4488/T/04

Europe -DG Health and Food Safety

2-10-2018

Rebetol (Merck Sharp and Dohme B.V.)

Rebetol (Merck Sharp and Dohme B.V.)

Rebetol (Active substance: ribavirin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6479 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/246/T83

Europe -DG Health and Food Safety

2-10-2018

PegIntron (Merck Sharp and Dohme B.V.)

PegIntron (Merck Sharp and Dohme B.V.)

PegIntron (Active substance: Peginterferon alfa-2b) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6484 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/280/T/135

Europe -DG Health and Food Safety

2-10-2018

Zoledronic acid Mylan (Mylan S.A.S.)

Zoledronic acid Mylan (Mylan S.A.S.)

Zoledronic acid Mylan (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)6486 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Docetaxel Teva (Teva B.V.)

Docetaxel Teva (Teva B.V.)

Docetaxel Teva (Active substance: Docetaxel) - Centralised - Yearly update - Commission Decision (2018)6463 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Xigduo (AstraZeneca AB)

Xigduo (AstraZeneca AB)

Xigduo (Active substance: dapagliflozin/metformin) - Centralised - Renewal - Commission Decision (2018)6462 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2672/R/44

Europe -DG Health and Food Safety

2-10-2018

Vfend (Pfizer Europe MA EEIG)

Vfend (Pfizer Europe MA EEIG)

Vfend (Active substance: voriconazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6490 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000387/T/0130

Europe -DG Health and Food Safety

2-10-2018

EU/3/11/909 (Janssen-Cilag International NV)

EU/3/11/909 (Janssen-Cilag International NV)

EU/3/11/909 (Active substance: Macitentan) - Transfer of orphan designation - Commission Decision (2018)6429 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/023/11/T/01

Europe -DG Health and Food Safety

2-10-2018

Vimizim (BioMarin International Limited)

Vimizim (BioMarin International Limited)

Vimizim (Active substance: elosulfase alfa) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6491 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/002779/T/0026

Europe -DG Health and Food Safety

2-10-2018

CoAprovel (Sanofi Clir SNC)

CoAprovel (Sanofi Clir SNC)

CoAprovel (Active substance: Irbesartan / hydrochlorothiazide) - Centralised - Yearly update - Commission Decision (2018)6465 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Zoledronic acid Teva (Teva B.V.)

Zoledronic acid Teva (Teva B.V.)

Zoledronic acid Teva (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)6466 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Celsentri (ViiV Healthcare BV)

Celsentri (ViiV Healthcare BV)

Celsentri (Active substance: maraviroc) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6467 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/811/T/56

Europe -DG Health and Food Safety

2-10-2018

ViraferonPeg (Merck Sharp and Dohme B.V.)

ViraferonPeg (Merck Sharp and Dohme B.V.)

ViraferonPeg (Active substance: Peginterferon alfa-2b) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6477 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/329/T/128

Europe -DG Health and Food Safety

2-10-2018

IntronA (Merck Sharp and Dohme B.V.)

IntronA (Merck Sharp and Dohme B.V.)

IntronA (Active substance: Interferon alfa-2b) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6487 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/281/T/116

Europe -DG Health and Food Safety

1-10-2018

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Active substance: Icatibant acetate) - Transfer of orphan designation - Commission Decision (2018)6432 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/054/02/T/01

Europe -DG Health and Food Safety

25-9-2018

Zonegran (Eisai GmbH)

Zonegran (Eisai GmbH)

Zonegran (Active substance: zonisamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6285 of Tue, 25 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/577/T/90

Europe -DG Health and Food Safety

5-9-2018

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations  https:

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations https:

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations https://go.usa.gov/xPcyB 

FDA - U.S. Food and Drug Administration

5-9-2018

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments:  h

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments: h

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments: https://go.usa.gov/xPcpT  pic.twitter.com/hAuLWaIYiK

FDA - U.S. Food and Drug Administration

4-9-2018

Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (Krka d. d., Novo mesto)

Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (Krka d. d., Novo mesto)

Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (Active substance: efavirenz / emtricitabine / tenofovir disoproxil) - Centralised - 2-Monthly update - Commission Decision (2018)5859 of Tue, 04 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4274/IB/02/G

Europe -DG Health and Food Safety